Skip to main content
Equibles
NRXP logo

NRXP · NRX Pharmaceuticals, Inc.

Track NRXP — free

Use NRXP with AI

Ask our own analyst here, or connect this data to the AI you already use.

Ask ALVIS about NRXP

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

ChatGPT Claude Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$3.27 -0.07 (-2.10%) At close · Aug 14
Going-concern doubt — flagged Aug 14, 2026

Substantial doubt about the company's ability to continue as a going concern.

“As such, the Company has concluded that substantial doubt exists regarding the Company's ability to continue as a going concern for a period of at least twelve months from the date of issuance of these consolidated financial statements.”
View the 10-Q filed Aug 14, 2026
Market Cap
$141.58M
Shares
43.30M

NRX Pharmaceuticals, Inc. Earnings Call Transcripts

Every quarterly earnings call for NRX Pharmaceuticals, Inc. (NRXP) — the full transcript with speaker labels, the audio replay, AI call highlights and a management-tone score, plus the matching 8-K earnings release and the quarter's 10-Q or 10-K. Investor days and conferences appear here too.

Revenue & result across quarters

Revenue Net income YoY up YoY down artefacts
· $ −$1.62M '24 Q3 24-11-15 · $ −$5.51M '25 Q1 25-05-31 · $ −$17.58M '25 Q2 25-08-20 · $242,000 −$5.89M '25 Q3 25-11-17 · $983,000 $361,000 '25 Q4 25-12-31 · $983,000 $361,000 '25 Q4 26-03-24 LATEST · $1.07M −$1.43M '26 Q1 26-05-18
Earnings call
FY26 · Q1
2026-05-18
Q1 2026 Financial Results Conference Call
Confident tone NRX-100 NDA and Regulatory Pathway NRX-101 and MIND-1 Trial Ketafree / Preservative-Free Ketamine Approval
Revenue
$1.07M
Rev · 5q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q4
2026-03-24
Q4 2025 Financial Results Conference Call
Confident tone FDA engagement and regulatory designations NRX100 NDA and real-world evidence pathway Hope Therapeutics subsidiary and clinic network
Revenue
$983,000*
Rev · 4q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY25 · Q4
2025-12-31
NRX Pharmaceuticals, Inc. Q4 FY2025 Earnings Call
Confident tone FDA engagement and regulatory designations NRX100 NDA and real-world evidence pathway Hope Therapeutics subsidiary and clinic network
Revenue
$983,000*
Rev · 4q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY25 · Q3
2025-11-17
NRX Pharmaceuticals, Inc. Q3 FY2025 Earnings Call
Positive tone Regulatory milestones (NRX-100, NRX-101, KETAFREE) ONE-D protocol / TMS + DCS HOPE Therapeutics clinic network
Revenue
$242,000
Rev · 4q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q2
2025-08-20
NRX Pharmaceuticals, Inc. Q2 FY2025 Earnings Call
Confident tone NRX100 ketamine regulatory progress Hope Therapeutics clinic subsidiary FDA accelerated pathways and CNPV
Revenue
$
Rev · 3q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q1
2025-05-31
NRX Pharmaceuticals, Inc. Q1 FY2025 Earnings Call
Confident tone NRX-100 NDA and regulatory progress NRX-101 oral combination for suicidality HOPE Therapeutics clinic network
Revenue
$
Rev · 2q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q4
2025-03-17
NRX Pharmaceuticals, Inc. Q4 FY2024 Earnings Call
Confident tone HOPE Therapeutics Clinic Roll-Up NRX-101 Bipolar Depression NRX-100 Preservative-Free Ketamine NDA
Results not yet reported
Audio Transcript Slides 8-K10-K
Earnings call
FY24 · Q3
2024-11-15
NRX Pharmaceuticals, Inc. Q3 FY2024 Earnings Call
Confident tone NRX-100 NDA progress NRX-101 oral treatment for suicidal bipolar depression Suicidality public health mission
Revenue
$
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q2
2024-08-15
NRX Pharmaceuticals, Inc. Q2 FY2024 Earnings Call
Confident tone NDA filings for NRX-100 and NRX-101 NRX-101 differentiation on safety (akathisia/suicidality) HOPE Therapeutics clinic roll-up
Results not yet reported
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q1
2024-04-02
NRX Pharmaceuticals, Inc. Q1 FY2024 Earnings Call
Confident tone NRX-101 in bipolar depression / akathisia HTX-100 (IV ketamine) for suicidal depression Regulatory and FDA pathway
Diluted EPS
$-0.74
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q4
2023-12-31
NRX Pharmaceuticals, Inc. Q4 FY2023 Earnings Call
Results not yet reported
Audio Transcript Slides 8-K10-K
Earnings call
FY23 · Q3
2023-11-14
NRX Pharmaceuticals, Inc. Q3 FY2023 Earnings Call
Diluted EPS
$-0.70
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q2
2023-06-30
NRX Pharmaceuticals, Inc. Q2 FY2023 Earnings Call
Diluted EPS
$-1.20
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q1
2023-03-31
NRX Pharmaceuticals, Inc. Q1 FY2023 Earnings Call
Diluted EPS
$-1.66
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q4
2023-03-31
NRX Pharmaceuticals, Inc. Q4 FY2022 Earnings Call
Results not yet reported
Audio Transcript Slides 8-K10-K
Earnings call
FY22 · Q3
2022-11-14
NRX Pharmaceuticals, Inc. Q3 FY2022 Earnings Call
Diluted EPS
$-1.40
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q2
2022-06-30
NRX Pharmaceuticals, Inc. Q2 FY2022 Earnings Call
Diluted EPS
$-1.10
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q1
2022-03-31
NRX Pharmaceuticals, Inc. Q1 FY2022 Earnings Call
Diluted EPS
$-2.10
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q4
2021-12-31
NRX Pharmaceuticals, Inc. Q4 FY2021 Earnings Call
Results not yet reported
Audio Transcript Slides 8-K10-K
Earnings call
FY21 · Q3
2021-09-30
NRX Pharmaceuticals, Inc. Q3 FY2021 Earnings Call
Diluted EPS
$-7.20
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q2
2021-06-30
NRX Pharmaceuticals, Inc. Q2 FY2021 Earnings Call
Diluted EPS
$-4.10
Audio Transcript Slides 8-K10-Q
Showing 1–21 of 21 earnings calls
Key facts CIK 1719406 CUSIP 629444209 13F (30d) 47 filings 47 filers Visit website Investor relations

Report a Problem

Category
Description
Email (optional, for follow-up)